RESIST ACINETO test for the rapid detection of NDM and OXA acquired carbapenemases directly from blood culture in Acinetobacter species

Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a significant global threat, leading to a high mortality rate associated with antimicrobial resistance (1). This multidrug- or extensively drug-resistant pathogen is identified by the WHO as one of the three critical priority bacteria requiring urgent development of new antibiotics (2). In Acinetobacter species, the major mechanism for carbapenem resistance is attributed to the production of carbapenem-hydrolysing class D beta-lactamases, including OXA-23, OXA-24/40, and OXA-58 groups (3). Additionally, emerging NDM class B metallo-beta-lactamases play a significant role in conferring resistance (4,5). Since the activity of the last-line antibiotics, such as the newly developed cefiderocol, depend on the type of carbapenemase, rapid detection of these carbapenemase-producing bacteria has become crucial for optimizing antibiotherapy in case of infection and implementing appropriate hygiene measures (6). In recent years, several rapid immunochromatographic tests (Coris BioConcept, NG Biotech) have been developed for the detection of carbapenemase-producing Enterobacterales; but none has been specifically designed for non-fermenting Gram-negative bacilli, with the exception of the Coris OXA-23 K-SET test (accurate detection of OXA-23 group carbapenemases) (7–9). The novel RESIST ACINETO test (Coris BioConcept) has recently been developed to detect the main carbapenemases identified in the Acinetobacter species, namely the OXA-23-, OXA-24/40-, OXA-58- and NDM-groups (10). Here, we evaluated the performance of this novel immunochromatographic assay for the detection of carbapenemase-producing Acinetobacter spp. encountered in mainland and overseas France, from standard and blood cultures.

A large collection of 121 well-characterised Acinetobacter spp. clinical strains were selected from the French National Reference Center for Antibiotic Resistance (FNRC-AR) (n=61) and the University hospital of Reunion Island (n=60). The isolates were identified to the species level using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MALDI Biotyper; Bruker Daltonics) or by sequencing. The collection included 107 isolates of A. baumannii calcoaceticus complex (A. baumannii n=95, A. pittii n=10, A. nosocomialis n=2), 7 A. ursingii, 1 A. haemolyticus, 1 A. johnsonii, 1 A. junii, 1 A. proteolyticus, 1 A. radioresistens, 1 A. townerii and 1 A. variabilis. One hundred and four strains produced one (n=75) or two carbapenemases (n=29) including 97 enzymes targeted by the test (27 OXA-23 type, 14 OXA-24/40 type, 6 OXA-58 type, 21 NDM type, 16 OXA-23+NDM-1, 3 OXA-58+NDM-1 and 10 others carbapenemase combinations) (Table S1). Three non-targeted carbapenemase, IMP-63 (n=1) et VIM-4 (n=2), were included, as well as 4 carbapenemase-hydrolyzing class D beta-lactamases (CHDL) rarely identified, OXA-235 (n=1), OXA-255 (n=2) and OXA-679 (n=1) (Table 1).

The performance of the RESIST ACINETO test was evaluated according to the manufacturer’s recommendations from standard and blood cultures. From bacterial colonies, a 1 μL full calibrated loop of bacteria grown for 16-24h at 35+/-2°C on Mueller-Hinton agar plate (bioMérieux) was added to 6 drops of lysis buffer. After homogenisation, 100 μl of the solution was added to the cassette. From blood culture, a blood culture vial (BACTEC Plus Aerobic/F, Becton Dickinson) was inoculated with 1 mL of a bacterial suspension calibrated at 10² UFC/mL and incubated. Then, 1mL of the positive blood culture was collected and treated with the RESIST-BC protocol, as recommended by the manufacturer (Figure S1). Finally, 100 μL of the extraction solution was transferred into the cassette. The reading of cassettes was performed by two operators in a double-blind after 15 min. The sensitivity and specificity of the tests were calculated using the online program of the VassarStats website (http://vassarstats.net).

For the 97 carbapenemase-producing strains targeted by the test, all enzymes were correctly detected from standard and blood cultures, except for the A. radioresistens isolate (OXA-23 + NDM-1), where both enzymes were only detected from the standard culture (Table 1). However, carbapenem resistant A. radioresistens isolates are very rare, representing less than 0.1% of Acinetobacter species received at the FNRC-AR between 2013 and 2023. Seven NDM-producing strains have a low intensity band particularly from blood culture, with no inter-operator discordance and was considered positive according to the manufacturer’s recommendations (Figure 1). Interestingly, the test detected in both growth conditions, the strains producing the OXA-255 (n=2) and OXA-679 (n=1) enzymes, which share 87% and 73% amino acid identity with OXA-24/40, respectively (these strains were considered true positives for the performance calculation) (15). However, the test failed to detect the OXA-235 enzyme, which shares an amino acid identity lower than 65% with the enzymes OXA-24/40 (59%), OXA-23 (61%), and OXA-58 (64%). No false positives were observed for the strains producing a non-targeted carbapenemase (IMP-63 and VIM-4) or other beta-lactamases (CTX-M-, GES-, PER-, CARB-, RTG-, TEM-types) (Table 1). The test exhibited a sensitivity of 100% in standard cultures and 99% in blood cultures, while demonstrating a specificity of 100% in both conditions. Thus, the RESIST ACINETO test proves to be a reliable method for detecting carbapenemases in Acinetobacter species, as demonstrated by two recent studies (10,11) focusing on standard cultures. In our study, we extended the evaluation to blood culture, revealing consistent results with the previous findings.

• Download figure
• Open in new tab

Figure 1.

Representation of RESIST ACINETO test results for some isolates of interest.

These results opens up new potential applications for the test based on blood cultures (11). The use of the RESIST ACINETO test could prove highly beneficial for countries with a high frequency of carbapenem-resistant Acinetobacter species isolates, particularly in cases where the A. baumannii-calcoaceticus complex is responsible for a significant proportion of healthcare-associated bacteremia (e.g. South East Asia and the Balkans) (12,13). When performed directly after the presumptive identification of Gram-negative (coco-)bacilli in a positive blood culture, this test could facilitate the early detection imipenem-resistant isolates. It may also enable the optimization of treatment based on the type of carbapenemase present. It is well established that the MIC of cefiderocol against NDM-producing A. baumannii isolates are typically higher than 2 mg/L (6). This test could further assist in directing treatment towards alternative therapeutic options.

In conclusion, the RESIST ACINETO test is a rapid, easy-to-use, and cost-effective test that demonstrates excellent performance in detecting the major acquired carbapenemases present in the Acinetobacter species. It has the potential to be considered as an option for routine use in microbiology laboratories.